ASHINGTON — The Food and Drug Administration will have to explain to a court this week why it won’t shed more light on an internal decision to allow at least two Americans who contracted Ebola to take a drug that wasn’t yet approved.

It’s the latest salvo in a legal case that could have broader implications for the ongoing campaign to pass a federal “right-to-try” law, in which advocates are aiming to help dying patients get access to other drugs the FDA hasn’t yet approved.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.